Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Probiotics

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Peptic Ulcer

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Massive subcutaneous emphysema after carbon dioxide mesotherapy.

Aesthetic plastic surgery·2013

Same author

Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice.

Gastroenterology·2010

Same author

Biomarkers of human gastrointestinal tract regions.

Mammalian genome : official journal of the International Mammalian Genome Society·2009

Same author

Yeast, beef and pork extracts counteract Clostridium difficile toxin A enterotoxicity.

FEMS microbiology letters·2009

Same author

Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota.

Genomics·2007

Same author

Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats.

The Journal of nutrition·2007

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Helicobacter pylori and probiotics.

Drahoslava Lesbros-Pantoflickova¹, Irène Corthésy-Theulaz, André L Blum

¹Department of Internal Medicine, Clinique Genolier, 1272 Genolier, Switzerland. draha.lesbros@wanadoo.fr

The Journal of Nutrition

|February 22, 2007

Summary

Probiotics show promise in managing Helicobacter pylori (H. pylori) infection by reducing inflammation and side effects associated with antibiotic treatment. While not eradicating the bacteria, long-term use may offer a beneficial approach for H. pylori-related gastric issues.

Related Experiment Videos

Last Updated: Jul 16, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Area of Science:

Microbiology
Gastroenterology
Immunology

Background:

Helicobacter pylori (H. pylori) infection is a widespread cause of gastritis, peptic ulcers, and gastric cancer.
Current antibiotic eradication therapies are effective but costly, leading to side effects and antibiotic resistance.
Probiotics offer a potential low-cost, scalable alternative for managing H. pylori colonization and associated conditions.

Purpose of the Study:

To evaluate the efficacy of probiotics in managing H. pylori infection and its related gastrointestinal disorders.
To assess the impact of probiotics on H. pylori density, inflammation, and treatment side effects.

Main Methods:

A comprehensive literature search of the MEDLINE database (1966-2006) was conducted.
Included studies encompassed in vitro, animal, and human trials investigating H. pylori and probiotics.
Data synthesis focused on probiotic effects on H. pylori inhibition, inflammation, eradication rates, and side effects.

Main Results:

Probiotics demonstrated in vitro inhibition of H. pylori and reduced gastric inflammation in animal models.
Seven of nine human studies reported improved H. pylori gastritis and decreased bacterial density with probiotic use.
Combination therapy with probiotics and antibiotics increased eradication rates (81% vs. 71%) and reduced side effects (23% vs. 46%) compared to antibiotics alone.

Conclusions:

Probiotic supplementation may favorably influence H. pylori infection by reducing gastric inflammation and mitigating antibiotic-associated side effects.
Long-term intake of probiotic strains could be beneficial for managing H. pylori-related conditions, though eradication was not achieved.
Probiotics represent a promising adjunctive or alternative strategy for H. pylori management, particularly in reducing the risk of severe gastric inflammation.